Product Description
Eli Lilly was developing ly-3025876, a Subcutaneous agent for Diabetes Mellitus, Type 2
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01870297 |
I6D-MC-SMRB | P1 |
Completed |
Type 2 Diabetes |
2014-12-01 |
2019-03-19 |
||
NCT01528124 |
I6D-FW-SMRA | P1 |
Completed |
Healthy Volunteers |
2012-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|